Lung Cancer Trials Ask AI to find trials
Active Not RecruitingPhase 3NCT04685135

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

Checked against the public recordLast updated Aug 11, 2026 · Source: ClinicalTrials.gov

StatusActive Not Recruiting
PhasePhase 3
U.S. locations380
SponsorMirati Therapeutics Inc.
01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 3
Sponsor
Mirati Therapeutics Inc.
Interventions being studied
Drug: MRTX849; Drug: Docetaxel
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
Biomarkers
KRAS→
Treatment approach
Targeted therapy→Chemotherapy→
Study topics
After prior treatment→
03
Public criteria

Who may be able to participate

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation. * Candidacy to receive treatment with docetaxel. Crossover Inclusion Criteria: * Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR * ECOG performance status 0-2 Exclusion Criteria: * Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib). * Active brain metastases. Crossover Exclusion Criteria: * Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Local Institution - 012-898Cerritos, California
  • Local Institution - 012-910Duarte, California
  • Local Institution - 012-898 DGlendale, California
  • Local Institution - 012-910-AHuntington Beach, California
  • Local Institution - 012-910-CIrvine, California
  • Local Institution - 012-910-BLong Beach, California
  • Local Institution - 012-910-FLong Beach, California
  • Local Institution - 012-910-DNewport Beach, California
  • Local Institution - 012-898 CSanta Ana, California
  • Local Institution - 012-858Santa Rosa, California
  • Local Institution - 012-910-ETorrance, California
  • Local Institution - 012-951-BDenver, Colorado

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 11, 2026. Always confirm current availability with the study team.

View original record ↗